摘要
目的:研究参灵肝康联合恩替卡韦治疗对慢性乙型病毒性肝炎及肝硬化患者肝纤维化疗效对肝功能的影响。方法:选取惠东县人民医院2018年6月-2020年6月收治的慢性乙型病毒性肝炎及肝硬化患者83例,随机分为研究组和对照组,分别为42例、41例,研究组采取参灵肝康联合恩替卡韦治疗,对照组采取恩替卡韦治疗,观察并比较两组患者的治疗效果、不良反应以及白蛋白(Albumin,ALB)、丙氨酸转氨酶(Alanine Aminotransferase,ALT)、谷草转氨酶(Aspartate Aminotransferase,AST)、总胆红素(Total Bilirubin,TBIL)等肝功能指标。结果:研究组治疗总有效率显著高于对照组(P <0.05);研究组不良反应总发生率显著低于对照组(P <0.05);研究组治疗后的ALB、ALT、AST、TBIL指标显著优于对照组(P <0.05)。结论:对慢性乙型病毒性肝炎及肝硬化患者采取参灵肝康联合恩替卡韦治疗,能够减少不良反应,优化肝功能指标,强化肝功能,治疗效果较好。
Objective:To study the effect of Shenling Gankang(参灵肝康)plus entecavir on liver fibrosis in patients with chronic hepatitis B and cirrhosis and liver function.Methods:83 patients with chronic hepatitis B and cirrhosis admitted to Huidong County People’s Hospital from June 2018 to June 2020 were randomly divided into the study group(42 cases)and the control group(41 cases).The study group was treated with Shenling Gankang plus entecavir,while the control group was treated with entecavir.The therapeutic effect,adverse reactions and liver function indexes such as ALB,ALT,AST and TBIL were observed and compared between the two groups.Results:The total effective rate in the study group was significantly higher than that in the control group(P<0.05).The total incidence of adverse reactions in the study group was significantly lower than that in the control group(P<0.05).ALB,ALT,AST and TBIL in the study group were significantly better than those in the control group(P<0.05).Conclusion:Shenling Gankang plus entecavir can reduce adverse reactions,optimize liver function indexes,strengthen liver function,and achieve better therapeutic effect in the treatment of chronic hepatitis B and cirrhosis.
出处
《中医临床研究》
2021年第33期102-104,共3页
Clinical Journal Of Chinese Medicine
基金
惠州市科技计划项目申报书(技术开发类)(200416114579882)。
关键词
慢性乙型病毒性肝炎
肝硬化
参灵肝康
肝功能
Chronic hepatitis B
Cirrhosis of the liver
Shenling Gankang
Liver function
